Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(62)

カスタマーフィードバック(10)

MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210 NFHMOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XQU|czKGh? NFvwZ2RFVVOR MVHJR|UxRTBwMECwNFch|ryP NITvcVkyPzl3NkC4NC=>
K562 M36wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi3NkBp NGK1Z2JFVVOR NGHPPHNKSzVyPUCuNFAyKM7:TR?= MXmxO|k2PjB6MB?=
M07e M1n6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmyVZd{PzJiaB?= M1vVR2ROW09? MoHKTWM2OD1yLkCwNVIh|ryP Mk\xNVc6PTZyOEC=
ALL3 MUHDfZRwfG:6aXOgRZN{[Xl? M3fLOVAvOc7:TR?= MmjsO|IhcA>? M{HwXWROW09? MV\JR|UxRTBwMECwOEDPxE1? MnvWNVk5QDl3NEC=
CML M{LKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiyNEBucW5? NH[wV3BFVVOR NEDpO3JKSzVyPUCuNFAyKM7:TR?= MkHUNVkzOTlyMU[=
BA/F3 M3XLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L4fVczKGh? NXv2fGlCTE2VTx?= NUfmeZdoUUN3ME22MlU5QSEQvF2= NV;Rc4FuOjNyOEi2OFQ>
BA/F3 NXyyRnhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:2T|czKGh? MVfEUXNQ M1PMNmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN M1iwc|I{ODh6NkS0
BA/F3 NIDzZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXVO|IhcA>? M2\1WGROW09? MljyTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>? M2DTSVI{ODh6NkS0
BA/F3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NkBp M3;0VWROW09? MWnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? MkLPNlMxQDh4NES=
BA/F3 NETuSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:4UlczKGh? MXPEUXNQ M33EdWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP NFi4SWkzOzNyMUewNy=>
BA/F3 M4K3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHUO|IhcA>? NGnKTnlFVVOR NUm5N2lSUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= MVSyN|MxOTdyMx?=
BA/F3 NIfEXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\mdmczPzJiaB?= MVTEUXNQ MUjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? NH7lXIEzOzNyMUewNy=>
BA/F3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXC[oJpPzJiaB?= NWTIXJg6TE2VTx?= NVfmd2tSUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= NWG1fFc2OjN|MEG3NFM>
BA/F3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG4VHJZPzJiaB?= M{\VWGROW09? NFjOfmRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= MlvQNlM{ODF5MEO=
BA/F3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn5Tog4OiCq M1z4VGROW09? NXrzUXc4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? MV[yN|MxOTdyMx?=
BA/F3 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzxOlU4PzJiaB?= MX7EUXNQ NILMN5ZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?= M4nEWlI{OzBzN{Cz
BA/F3 NFHlOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TyZVczKGh? NIGxeY5FVVOR M1[zTWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO NV3SV2xFOjN|MEG3NFM>
BA/F3 NIrkdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX2OoVwPzJiaB?= NEC2b|JFVVOR NG\rZZlKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= MYGyN|MxOTdyMx?=
T cell NWDrbmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXi3NkBp NY[0cpZmTE2VTx?= Mke0TY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> MlLvNVcyPTR3MUK=
WiDr MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[0Zlc4OiCq Mk[2SG1UVw>? MnLvTWM2OD1yLkC1NkDPxE1? NXz0OI9COTV4MUW1NVI>
PC3 NIHkbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfwcZE4OiCq M1TIPWROW09? M1jLSGlEPTB;MD6wNFk1KM7:TR?= NYPIWlc4OTV4MUW1NVI>
MDA-MB-231 NU\0TmtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp NXfqeXR7TE2VTx?= MmrvTWM2OD1yLkCxNkDPxE1? MkHrNVU3OTV3MUK=
Hs578T MVfDfZRwfG:6aXOgRZN{[Xl? M1[wRlczKGh? MnPUSG1UVw>? Mn7DS2k2OD1yLkCzJO69VQ>? NYD5S4VWOjRyMUWzNlc>
HMEC MUnDfZRwfG:6aXOgRZN{[Xl? NH\Ee|g4OiCq M{jRdmROW09? NFXsemtIUTVyPUGuPEDPxE1? NVn1SoU4OjRyMUWzNlc>
DU145 MXTDfZRwfG:6aXOgRZN{[Xl? NHjne4c4OiCq MVHEUXNQ M3XoRmdKPTB;MD6xOkDPxE1? Mm\JNlQxOTV|Mke=
U251 NHzsV3VEgXSxdH;4bYMhSXO|YYm= NGHMNnY4OiCq MnXzSG1UVw>? NYDZZnROT0l3ME2yMlgyKM7:TR?= NIflUmozPDBzNUOyOy=>
NCI60 M3jBd2N6fG:2b4jpZ{BCe3OjeR?= M2DWU|czKGh? NYXFZ21DTE2VTx?= M4W2S2dKPTB;NT63JO69VQ>? NFHaSoIzPDBzNUOyOy=>
MALME-3M M4GzdGN6fG:2b4jpZ{BCe3OjeR?= MmDvO|IhcA>? NWG1ZXFXTE2VTx?= Mom0S2k2OD14Lk[xJO69VQ>? NIDwdWozPDBzNUOyOy=>
KM12 NEW3[HZEgXSxdH;4bYMhSXO|YYm= MUi3NkBp M2e5fGROW09? NVLaWHJPT0l3ME23MlQ1KM7:TR?= NYjESZExOjRyMUWzNlc>
SW620 MV3DfZRwfG:6aXOgRZN{[Xl? MXK3NkBp MkXCSG1UVw>? NIHMXGxIUTVyPUiuOFMh|ryP M3;YeVI1ODF3M{K3
RXF 393NL M1:zOGN6fG:2b4jpZ{BCe3OjeR?= NHLFXlc1KGSjeYO= M4DwUmROW09? NXHZT3JwUUN3ME2wMlAzOTdizszN M37XT|I{OjV|MEe0
LXFA 983L NX:0T293S3m2b4TvfIlkKEG|c3H5 MVO0JIRigXN? MknCSG1UVw>? MXXJR|UxRTBwMEW2OUDPxE1? MVWyN|I2OzB5NB?=
PRXF DU145 NX35RYRoS3m2b4TvfIlkKEG|c3H5 M1jsVFQh\GG7cx?= NXjQVXBrTE2VTx?= NHrE[HZKSzVyPUCuNFYzOyEQvF2= NEnLSVczOzJ3M{C3OC=>
PAXF 1657L Mk\WR5l1d3SxeHnjJGF{e2G7 NUC0TFNNPCCmYYnz NV3LSmVFTE2VTx?= NGnWSJhKSzVyPUCuNVIyKM7:TR?= M{L0clI{OjV|MEe0
CXF 1103L NXTNSVJPS3m2b4TvfIlkKEG|c3H5 M1jSWVQh\GG7cx?= MYTEUXNQ NVfqWmRIUUN3ME20MlM3KM7:TR?= M1S2e|I{OjV|MEe0
GXF251L MUTDfZRwfG:6aXOgRZN{[Xl? NYPwb2JrPCCmYYnz NYjqOmNlTE2VTx?= NWXWVFgyUUN3ME2yMlI2KM7:TR?= NI\zT3MzOzJ3M{C3OC=>
NCI-H23 NGH6OplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp Mlz2SG1UVw>? MmG2TWM2OD1{LkK3JO69VQ>? MViyN|UzOTB{MB?=
HCT116 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLMO|IhcA>? NYXSXY0zTE2VTx?= MonUTWM2OD1{LkOg{txO NYLwS4pwOjN3MkGwNlA>
MCF7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XLelczKGh? MmnISG1UVw>? NELkUlBKSzVyPUKuOVch|ryP MXmyN|UzOTB{MB?=
NCI-H460 NFPt[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv2SFk4OiCq M1Huc2ROW09? M1zuWGlEPTB;OD65PUDPxE1? NVT2V3R3OjN3MkGwNlA>
DLD1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfJO|IhcA>? M3n3ZWROW09? MnjPTWM2OD12Lk[g{txO MV:yN|U3Pzl4MB?=
NCI-H661 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fDSVczKGh? MofjSG1UVw>? NGHwUG5KSzVyPUeuPEDPxE1? MX6yN|U3Pzl4MB?=
A549 NVG1doxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW3NkBp M{nCd2ROW09? M4rqZ2lEPTB;OD6yJO69VQ>? MXyyN|U3Pzl4MB?=
U937 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC3NkBp M3K1O2ROW09? M{PJcGlEPTB;MUKuNkDPxE1? MViyN|U3Pzl4MB?=
HEK293 MmTDSpVv[3Srb36gRZN{[Xl? MVixNOKh|ryP NV3wZodsTE2VTx?= NYPh[nhsUW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> MX2yNlc4ODZzMB?=
HUVEC NV\GdWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HNVFAvOTYEoN88US=> MY[3NkBp M2Ho[mROW09? NIf1ZoNKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> MVSyNlg2Ozl7Mx?=
HUVEC Ml61SpVv[3Srb36gRZN{[Xl? NUPBcWN{OTYEoN88US=> NHzIUlM4OiCq MnfGSG1UVw>? M4D4UGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO MljwNlI5PTN7OUO=
Plasmodium falciparum MnfmSpVv[3Srb36gRZN{[Xl? MVWxNOKh|ryP NGDQ[|YyPSCvaX6= MnfESG1UVw>? M1W2c2lvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? MVyyOFU2ODN|MB?=
PC3 NVnwW3JjTnWwY4Tpc44hSXO|YYm= M{PDVFAvOSEQvF2= NFO5dnE2KGh? NIHsdHRFVVOR M{T1e2lvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MYSxPVQ3Ojl5NR?=
DU145 NF24Vo5HfW6ldHnvckBCe3OjeR?= NWLIfXI1OC5zIN88US=> MVW1JIg> MnfBSG1UVw>? M{HwcmlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N M2ryNlE6PDZ{OUe1
PC3 MkLzT4lv[XOnIFHzd4F6 NG\TO|AxNjFizszN M3K1RVUhcA>? MoPuSG1UVw>? MUXJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P MoO0NVk1PjJ7N{W=
DU145 MUjLbY5ie2ViQYPzZZk> M125cFAvOSEQvF2= M{i3SFUhcA>? MlLoSG1UVw>? NGHXUXJKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MmHuNVk1PjJ7N{W=
PC3 NIXjRVJMcW6jc3WgRZN{[Xl? MWqwMlEh|ryP M13QRVUhcA>? MmrBSG1UVw>? MnThTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O NGPpTIcyQTR4Mkm3OS=>
DU145 Ml;XT4lv[XOnIFHzd4F6 NF\JRoExNjFizszN MUO1JIg> NFfoZWxFVVOR MoryTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? MlrCNVk1PjJ7N{W=
Huh7 MXfBcpRqfmm{YXygRZN{[Xl? NYGwZo1DOi53IN88US=> NEm1XIw1KGSjeYO= MnzzSG1UVw>? MW\Jcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? M4TxW|E4OzZyNke2
C6/36 MoTNRY51cX[rcnHsJGF{e2G7 NWe0UFJWOi53IN88US=> NV;HWGV5PCCmYYnz NWK3XHdsTE2VTx?= MWrJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO MlqxNVc{PjB4N{[=
U937 MYnGeY5kfGmxbjDBd5NigQ>? MnvKNUDPxE1? NF7VNYUyKGh? NX;LRmJYTE2VTx?= NVHJPXVlWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= MUmxO|Y5PDB7OR?=
U937 NEjXdWhHfW6ldHnvckBCe3OjeR?= MUexJO69VQ>? NFnS[4UyKGh? MXjEUXNQ MVnS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> M330[VE4Pjh2MEm5
murine mast cell MUHGeY5kfGmxbjDBd5NigQ>? MVexJO69VQ>? NE\TZYszPCCq NHnGNYVFVVOR MlXmTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? NEnjSXYyPzZ6NEC5PS=>
BV-173 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T6VWlEPTB;MD6wNFAxODBzMEmg{txO MVrTRW5ITVJ?
K-562 NFfPUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jycGlEPTB;MD6wNFAxODB{Nk[g{txO NFW5e4tUSU6JRWK=
BL-70 NGfN[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jnZWlEPTB;MD6wNFAxODB6MkKg{txO NGD0eINUSU6JRWK=
EM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3pXFM3UUN3ME2wMlAxODByMUC4JO69VQ>? M3zQd3NCVkeHUh?=
LAMA-84 MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3LTWM2OD1yLkCwNFAxOzJzIN88US=> NGHU[WZUSU6JRWK=
MEG-01 NEH1[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPtTWM2OD1yLkCwNFAxQThizszN MVnTRW5ITVJ?
EoL-1-cell M4TUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXZTWM2OD1yLkCwNFAyOzFizszN NIG1NYRUSU6JRWK=
CTV-1 M2fYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMECwNFQxPCEQvF2= MmDEV2FPT0WU
TE-15 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMEC1PFkh|ryP MULTRW5ITVJ?
NOS-1 M13tdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7zXHNTUUN3ME2wMlAxPjF|IN88US=> MWjTRW5ITVJ?
D-336MG MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\adWlEPTB;MD6wNFY{KM7:TR?= MYnTRW5ITVJ?
LB1047-RCC NVnPfm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\1ZmlEPTB;MD6wNFk5QSEQvF2= M4LPVHNCVkeHUh?=
LB996-RCC MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTNVnB4UUN3ME2wMlAxQTlzIN88US=> M3rEZnNCVkeHUh?=
SW982 M3HO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInsfFBKSzVyPUCuNFEyOTVizszN M1SwTnNCVkeHUh?=
TK10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vGOGlEPTB;MD6wNVE4PCEQvF2= M4\UbnNCVkeHUh?=
A704 NUnL[Wk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHPTWM2OD1yLkCxOFkyKM7:TR?= M{fRfXNCVkeHUh?=
TE-8 M13zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXqWlZKSzVyPUCuNFE2PzZizszN M37LRXNCVkeHUh?=
DOHH-2 M4LZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L6NGlEPTB;MD6wNVcyQSEQvF2= NIDIbG5USU6JRWK=
HOP-62 NUDDNIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEG4N|Qh|ryP MkjWV2FPT0WU
TE-12 NE\BV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nZUGlEPTB;MD6wNVg3OSEQvF2= NIjOe4VUSU6JRWK=
KGN NF3TZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPwTWM2OD1yLkCxPVQzKM7:TR?= NIjnU|dUSU6JRWK=
NCI-H1648 NIS1SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPMRpFKSzVyPUCuNFIxOTFizszN MmfDV2FPT0WU
OS-RC-2 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\kS41KSzVyPUCuNFIxOyEQvF2= NFTibYRUSU6JRWK=
GB-1 NXXsXHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHDcmpKSzVyPUCuNFIyPTdizszN NGWzbGFUSU6JRWK=
RXF393 NV3G[pFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lie2lEPTB;MD6wNlM2PyEQvF2= M3[ye3NCVkeHUh?=
LC-2-ad MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\RemlEPTB;MD6wNlU5PiEQvF2= MoP2V2FPT0WU
KS-1 NVWyPVNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULVeYdPUUN3ME2wMlAzPzNizszN MlvrV2FPT0WU
ETK-1 NUXPZo5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEK4N|Ih|ryP NFzPdJNUSU6JRWK=
SW954 NWq2d|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyxUWRXUUN3ME2wMlAzQTJ5IN88US=> NF\pdYhUSU6JRWK=
Becker MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID4Nm1KSzVyPUCuNFMxODNizszN NVfKUYM5W0GQR1XS
MZ1-PC NGPteJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLPTWM2OD1yLkCzNVE6KM7:TR?= Mn75V2FPT0WU
ES6 NXXHPIp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfFTWM2OD1yLkCzNVk{KM7:TR?= NU\LTYNjW0GQR1XS
KURAMOCHI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PzOWlEPTB;MD6wN|Q5PyEQvF2= MkG1V2FPT0WU
CGTH-W-1 M{XCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXtTWM2OD1yLkCzOVQ5KM7:TR?= NF\ENHFUSU6JRWK=
VA-ES-BJ M{PudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEO5NFIh|ryP Mmq1V2FPT0WU
LXF-289 NHu5eJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKwWIF[UUN3ME2wMlA{QTV4IN88US=> M1\R[XNCVkeHUh?=
MPP-89 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:3TWM2OD1yLkC0NFQ6KM7:TR?= NGnBTGVUSU6JRWK=
SW872 NGnvU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r5W2lEPTB;MD6wOFE3OSEQvF2= MmG3V2FPT0WU
SNB75 NED2VmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTZNmNHUUN3ME2wMlA1PDN3IN88US=> M4\nPHNCVkeHUh?=
PSN1 NX\FZVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMES0O|Qh|ryP NGOyV5dUSU6JRWK=
LB831-BLC NIDLUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrzXlBKSzVyPUCuNFQ3ODlizszN M4Tsb3NCVkeHUh?=
MFH-ino NHvtNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nnUWlEPTB;MD6wOFczPCEQvF2= MVPTRW5ITVJ?
TGBC24TKB MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMES3OlEh|ryP MWDTRW5ITVJ?
A388 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSzUVdMUUN3ME2wMlA2ODl3IN88US=> MUjTRW5ITVJ?
BB30-HNC MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEW0N|ch|ryP MYrTRW5ITVJ?
GI-ME-N M3TlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4mzW2lEPTB;MD6wOlEyQCEQvF2= MU\TRW5ITVJ?
TGBC1TKB Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLtXVRFUUN3ME2wMlA3OTZ2IN88US=> MoLMV2FPT0WU
TE-10 M{Lle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD1yLkC2N|U4KM7:TR?= NUXGdlFWW0GQR1XS
A498 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLaT4xnUUN3ME2wMlA4Ojh2IN88US=> M4fQfXNCVkeHUh?=
TE-11 M4jpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\weGlEPTB;MD6wO|g2QCEQvF2= M1nVd3NCVkeHUh?=
BB65-RCC NUC3R2Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvoeVhqUUN3ME2wMlA5OjJ5IN88US=> NV65RZl2W0GQR1XS
C2BBe1 NVW5[oNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfrW5hKSzVyPUCuNFg{ODhizszN NVHicHhkW0GQR1XS
NCI-H747 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMEizOlIh|ryP M1vXOHNCVkeHUh?=
IST-MES1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX3TWM2OD1yLkC4OVUzKM7:TR?= MVTTRW5ITVJ?
KALS-1 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2izTGlEPTB;MD6wPVQ6KM7:TR?= NH:0WYdUSU6JRWK=
GCIY MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG1S2QxUUN3ME2wMlA6PjV4IN88US=> MlnGV2FPT0WU
RL95-2 NFXxWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL3TXBKSzVyPUCuNVA{QCEQvF2= MmCxV2FPT0WU
TE-1 NHTyW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWwTWM2OD1yLkGwOVQh|ryP MVTTRW5ITVJ?
NCI-H1355 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ZTWM2OD1yLkGxNFI5KM7:TR?= M{nNVXNCVkeHUh?=
SW962 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMUGyPVIh|ryP M3LtcnNCVkeHUh?=
KLE Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMUGzNVch|ryP MnzhV2FPT0WU
MC116 M2S5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGxdVBKSzVyPUCuNVE1OSEQvF2= MULTRW5ITVJ?
NMC-G1 M3z3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXFVFVoUUN3ME2wMlEyPjB4IN88US=> NW\JfopZW0GQR1XS
KU812 NWnrZ3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\jTWM2OD1yLkGxPFg{KM7:TR?= NFXoUnRUSU6JRWK=
COLO-829 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfjZnFKSzVyPUCuNVIzOTNizszN MVrTRW5ITVJ?
NTERA-S-cl-D1 NV3UcmFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm4R5FKSzVyPUCuNVIzQDNizszN NEHvfFlUSU6JRWK=
IST-MEL1 NUXyUmhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELWV2VKSzVyPUCuNVM1PSEQvF2= NV;QW|VEW0GQR1XS
MLMA MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn4U5dKSzVyPUCuNVQxOzJizszN MXjTRW5ITVJ?
LS-123 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TDUmlEPTB;MD6xOFA3PCEQvF2= NH7tNXlUSU6JRWK=
LB2518-MEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMUSxOlIh|ryP Mkj3V2FPT0WU
NB69 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\ud2lEPTB;MD6xOFQ{PiEQvF2= M{LrTnNCVkeHUh?=
8-MG-BA MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O1bWlEPTB;MD6xOVQ2QCEQvF2= MXzTRW5ITVJ?
K5 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfrTWM2OD1yLkG2OFg6KM7:TR?= MlTvV2FPT0WU
KINGS-1 M{iyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMU[2OlYh|ryP NIL4So1USU6JRWK=
SF268 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHOWYNpUUN3ME2wMlE4PDB2IN88US=> MVfTRW5ITVJ?
PF-382 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnwToRPUUN3ME2wMlE4Pjd6IN88US=> M1rmXnNCVkeHUh?=
SH-4 NV3kUlFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjid21VUUN3ME2wMlE5PDF|IN88US=> NHPTclZUSU6JRWK=
NALM-6 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X4Z2lEPTB;MD6xPVI6PSEQvF2= M2Hte3NCVkeHUh?=
CP66-MEL MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMUm1N|Eh|ryP Ml3NV2FPT0WU
697 NUHaTZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2zT3BKSzVyPUCuNVk6QDdizszN NF7K[2dUSU6JRWK=
CP67-MEL NUHDfpE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkC0PFgh|ryP NEXHUWVUSU6JRWK=
DSH1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMkSwNFEh|ryP MlzwV2FPT0WU
HCE-4 M3uyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMk[0N|kh|ryP Mn[1V2FPT0WU
MZ2-MEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfCfFdbUUN3ME2wMlI5PTN5IN88US=> NGnUb4FUSU6JRWK=
BL-41 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMkmxNlMh|ryP MWLTRW5ITVJ?
HUTU-80 NH\DdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwM{G0NkDPxE1? NI\QPIdUSU6JRWK=
LOXIMVI NHfjNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfGRXBGUUN3ME2wMlMyPTB|IN88US=> NGfIdGJUSU6JRWK=
no-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HwT2lEPTB;MD6zNVk{OSEQvF2= M1jsNXNCVkeHUh?=
KARPAS-422 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPHW|lKSzVyPUCuN|M6QTdizszN Mme5V2FPT0WU
SW684 NF\2UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLWW4J7UUN3ME2wMlM1QThizszN NGPQWXRUSU6JRWK=
SF126 NWTDNVg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwM{W0NUDPxE1? MliwV2FPT0WU
D-263MG NIP4Om5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi5[2JKSzVyPUCuN|YzOjRizszN NUXqVWZpW0GQR1XS
OVCAR-4 M2fvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\LTWM2OD1yLkO3OFM{KM7:TR?= NVz5doxuW0GQR1XS
BB49-HNC M1L2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKwd|dKSzVyPUCuN|g2QTlizszN MUHTRW5ITVJ?
ONS-76 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jG[WlEPTB;MD60Nlk2OSEQvF2= M2nYV3NCVkeHUh?=
MZ7-mel MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q0S2lEPTB;MD60O|kyOSEQvF2= Ml\GV2FPT0WU
RCC10RGB M1PueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r2bGlEPTB;MD60PVEyKM7:TR?= MnHJV2FPT0WU
BOKU NEPDVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEmxN|Mh|ryP NYXpfGtbW0GQR1XS
no-11 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnryTWM2OD1yLkWwNlI5KM7:TR?= MX;TRW5ITVJ?
IST-SL2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDRTWM2OD1yLkWwN|AzKM7:TR?= M3XuTXNCVkeHUh?=
RKO M1u4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwNUK5OlYh|ryP NEDTNXhUSU6JRWK=
HT-144 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfOPJFKSzVyPUCuOVM3ODlizszN MXrTRW5ITVJ?
NCI-H446 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfXeZBKSzVyPUCuOlI4PiEQvF2= NHK0PXVUSU6JRWK=
QIMR-WIL NEK1VFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGyNGZLUUN3ME2wMlcxPjJ7IN88US=> Mlj2V2FPT0WU
MHH-PREB-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXjTIZKSzVyPUCuO|Q1PjlizszN NYjTZ5ZFW0GQR1XS
EW-16 NIXXfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG3TWM2OD1yLke2NVc5KM7:TR?= MnHKV2FPT0WU
EW-24 NUi1fY83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnFTWM2OD1yLke4NVY2KM7:TR?= MXXTRW5ITVJ?
LB373-MEL-D M{mySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2roVGlEPTB;MD64NlUxQCEQvF2= MY\TRW5ITVJ?
TE-9 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwOEe1N|Ih|ryP NIft[3hUSU6JRWK=
A3-KAW M4LJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwOUi0OVIh|ryP M3P2WnNCVkeHUh?=
A101D M1[3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDZPY5VUUN3ME2xMlA{ODR|IN88US=> M3Ts[XNCVkeHUh?=
OCUB-M NWXibot3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\IeIpKSzVyPUGuNFQ1OTJizszN NH;pS2JUSU6JRWK=
ES4 NWfFNYRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvxTWM2OD1zLkC1NVQ2KM7:TR?= NELlcmJUSU6JRWK=
TE-6 M1vwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDTenhKSzVyPUGuNlEzOjZizszN MXnTRW5ITVJ?
D-502MG NYO0VHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH5bFY1UUN3ME2xMlI{Ozd4IN88US=> NFriVZlUSU6JRWK=
KNS-42 MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfzTWM2OD1zLkK0OFEzKM7:TR?= NUe3PWJ3W0GQR1XS
SNU-C2B MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH0TWM2OD1zLkOwOVg6KM7:TR?= MmPyV2FPT0WU
NCI-H1838 M125Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljUTWM2OD1zLkOwO|M{KM7:TR?= MY\TRW5ITVJ?
NKM-1 NXzrcIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDGd4oyUUN3ME2xMlMxQDV7IN88US=> M4e4PHNCVkeHUh?=
GI-1 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i2WmlEPTB;MT6zOlIzKM7:TR?= M1ezXnNCVkeHUh?=
NB5 M1;ibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwM{m4Nlch|ryP M{nlUnNCVkeHUh?=
CAS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13FVGlEPTB;MT60NFk6OiEQvF2= MlzZV2FPT0WU
HCE-T NIjnSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rjXWlEPTB;MT61OlcyPCEQvF2= MYjTRW5ITVJ?
SBC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\vVIgxUUN3ME2xMlU4QTh2IN88US=> NUD0NmxlW0GQR1XS
JiyoyeP-2003 NFfmdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TH[WlEPTB;MT63N|Q3PiEQvF2= NH3ndHhUSU6JRWK=
TE-5 NIjxXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXZXY5[UUN3ME2xMlc6OTN7IN88US=> NWfPPZJwW0GQR1XS
CAN MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPFUXRKSzVyPUGuPFIzPTJizszN NYDKeZV[W0GQR1XS
SK-UT-1 M{H4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwMU[2PVMh|ryP NHfRZ|RUSU6JRWK=
JVM-2 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJwM{[yPFQh|ryP MoTyV2FPT0WU
LB771-HNC M1vqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwNUe1OVEh|ryP M2j6TnNCVkeHUh?=
NCCIT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwOE[2NVYh|ryP NIG2cGhUSU6JRWK=
NCI-H2126 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[1SWlEPTB;Mj64O|U2OiEQvF2= MoPRV2FPT0WU
Calu-6 NF3RcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXJPIpKSzVyPUOuNFU4PDFizszN NGO5fHBUSU6JRWK=
SK-LMS-1 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDv[lJKSzVyPUOuNVE5QDZizszN MUfTRW5ITVJ?
ARH-77 M2naN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;uTWM2OD1|LkS2PVE2KM7:TR?= NXX0T2VNW0GQR1XS
NB17 MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmxdGhKSzVyPUOuOlM5PDdizszN NHnmPFRUSU6JRWK=
A253 NX;VeVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jBSWlEPTB;Mz63N|I1PiEQvF2= MWHTRW5ITVJ?
OPM-2 NGLtSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRwMke2PFUh|ryP NWfJOWRVW0GQR1XS
MV-4-11 NFm0dJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWruV3VWUUN3ME20MlM3PDV2IN88US=> MVjTRW5ITVJ?
SR MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwNEm5OVQh|ryP M3X3VHNCVkeHUh?=
KG-1 NGrwWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS5TZpKSzVyPUSuOlA5PDVizszN NH;NWVNUSU6JRWK=
OCI-AML2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3HTWpKSzVyPUWuPFYyPTRizszN NV[xT|UyW0GQR1XS
D-247MG MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC1[Y5KSzVyPU[uNVI2OTlizszN M1Xp[HNCVkeHUh?=
DJM-1 NVrvbnM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LFWmlEPTB;Nj60PFU2QCEQvF2= NVHLeoZyW0GQR1XS
RPMI-6666 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7QflhKSzVyPUeuNlcxPjdizszN M4HhOHNCVkeHUh?=
KARPAS-45 NE\H[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTdwNUG2O|Eh|ryP MWfTRW5ITVJ?
LP-1 M{LpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUizd2l3UUN3ME23MlU1Pzh{IN88US=> M1LGWXNCVkeHUh?=
RS4-11 M3nFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j4PWlEPTB;Nz62OVc5PyEQvF2= NEjzUVVUSU6JRWK=
DU-4475 NV3iPJVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PmSWlEPTB;OD6yNVY2OiEQvF2= NULnbFlSW0GQR1XS
MONO-MAC-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLFV|dnUUN3ME24MlI4ODZ4IN88US=> MnPXV2FPT0WU
NCI-SNU-16 Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRThwNU[xNlgh|ryP MVnTRW5ITVJ?
SJSA-1 NVryUoJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\y[2JKSzVyPUiuO|I5ODVizszN NF32fJlUSU6JRWK=
MMAC-SF M320cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDLUmRKSzVyPUiuO|k{ODdizszN NEey[YFUSU6JRWK=
SK-NEP-1 NFPCZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRThwOEmxOVUh|ryP Ml7XV2FPT0WU
J-RT3-T3-5 NHn3c2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor3TWM2OD16Lkm2OVI6KM7:TR?= NU\ocI1bW0GQR1XS
SKM-1 NFfDUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\rcWNKSzVyPUmuNFE4OzRizszN NGPJOFRUSU6JRWK=
LB2241-RCC NF\WO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTlwMEKwNVIh|ryP NHe4d|JUSU6JRWK=
SIG-M5 Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXNTWM2OD17LkCyOFk{KM7:TR?= M3HH[HNCVkeHUh?=
EVSA-T NYTlUXlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHxeZBMUUN3ME25MlI4Pzl|IN88US=> MXzTRW5ITVJ?
GT3TKB NW\Uc3R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnpVHlKUUN3ME25MlM2PTR4IN88US=> NF;mS4hUSU6JRWK=
NB6 M{TNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonvTWM2OD17LkmyNlU6KM7:TR?= NFOybXRUSU6JRWK=
EHEB NWrjVYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WzTGlEPTB;MUCuNFY2PiEQvF2= MUXTRW5ITVJ?
HEL NIT6O4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{eyb2lEPTB;MUCuOFc4PiEQvF2= MY\TRW5ITVJ?
ALL-PO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\GTWM2OD1zMD63PVM5KM7:TR?= NHXPZWVUSU6JRWK=
TGW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXCXmRKSzVyPUGxMlI5OjhizszN NHy0TVBUSU6JRWK=
BC-3 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXjTWM2OD1zMj6xNVM5KM7:TR?= M1z1d3NCVkeHUh?=
IA-LM M3LaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17vNmlEPTB;MUKuOFQ1PSEQvF2= M2rZeHNCVkeHUh?=
UACC-257 NWTRbm12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LUfWlEPTB;MUKuPVE6QCEQvF2= MVvTRW5ITVJ?
KP-N-YS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHJTWM2OD1zMj65Nlg{KM7:TR?= MlLuV2FPT0WU
Raji MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\iTWM2OD1zMz63OFk4KM7:TR?= MknaV2FPT0WU
SF539 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHDTWM2OD1zMz64OVU4KM7:TR?= M1jhOXNCVkeHUh?=
DMS-153 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPqTHZKSzVyPUG0MlAxOjhizszN NHXsTHRUSU6JRWK=
L-540 NWnsdWo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF3LkC2O|Ih|ryP MmC1V2FPT0WU
MN-60 NIPJVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF3LkG5O|kh|ryP MWrTRW5ITVJ?
RPMI-8866 M3\UTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF5LkS0OVQh|ryP M4LOZXNCVkeHUh?=
NCI-H510A NITacJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfETWM2OD1zOT6zPVc{KM7:TR?= MYHTRW5ITVJ?
NB13 NInVRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESyWHdKSzVyPUG5MlQ5PzdizszN NFTHO25USU6JRWK=
HAL-01 NI\MfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rl[2lEPTB;MUmuO|U1OyEQvF2= NFjkcnlUSU6JRWK=
NCI-H720 NVvmTmc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjJTWM2OD1{MD6yO|M{KM7:TR?= NET2TZlUSU6JRWK=
REH M1T6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ruSGlEPTB;MkCuOlM2PyEQvF2= MV3TRW5ITVJ?
KNS-81-FD NXHaVFlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\5TWM2OD1{Mz6xOFYh|ryP MXnTRW5ITVJ?
HC-1 NUfL[Gk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS4TWM2OD1{ND61OVUyKM7:TR?= MWrTRW5ITVJ?
NCI-H2141 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCxTWM2OD1{ND63O|U1KM7:TR?= MVjTRW5ITVJ?
MOLT-4 NXPIbXo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVftV4lmUUN3ME2yOk43PzV|IN88US=> M3jVRXNCVkeHUh?=
OMC-1 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3vT49KSzVyPUK3MlE1OjJizszN MU\TRW5ITVJ?
LC-1F NEjRZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PBbGlEPTB;MkeuN|I1PSEQvF2= M{jRcnNCVkeHUh?=
NCI-H1304 NEm5bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3mXGFKSzVyPUK4MlE3OjhizszN MXTTRW5ITVJ?
BC-1 NU\SbWcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ6Lk[1NUDPxE1? NUDyUppMW0GQR1XS
NCI-H64 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zVOmlEPTB;MkmuOlI2OyEQvF2= NUHWUnB[W0GQR1XS
MOLT-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T2VmlEPTB;MkmuOlI6OiEQvF2= MWnTRW5ITVJ?
U-87-MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu3SZB7UUN3ME2zNE44PjZizszN NE\BTHdUSU6JRWK=
GAK M2LU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOwTWM2OD1|MT6yOlg3KM7:TR?= MlT5V2FPT0WU
ES8 NIXMO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe0Tnd1UUN3ME2zNk4yOjV{IN88US=> NWHTTFFFW0GQR1XS
HCC1599 NGPvfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjBN45KSzVyPUOyMlM{OjVizszN MWfTRW5ITVJ?
EB-3 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDZTWM2OD1|ND6zNVE4KM7:TR?= NWPtWlYxW0GQR1XS
HCC1187 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN3LkiwOVIh|ryP M{n6OnNCVkeHUh?=
SK-PN-DW MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TXUWlEPTB;M{[uNVk1OyEQvF2= MVLTRW5ITVJ?
JVM-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rMR2lEPTB;M{euNlM{QCEQvF2= NEXPcW1USU6JRWK=
HCC2157 M1fwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYqySHM6UUN3ME2zO{46QTR4IN88US=> MnrQV2FPT0WU
A4-Fuk NUDNcIt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO5TWM2OD1|OD6xNFA6KM7:TR?= NEH4XXNUSU6JRWK=
COR-L279 NFOxZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XLT2lEPTB;NECuNlg2OSEQvF2= MWjTRW5ITVJ?
DEL NWTJdXdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{iybWlEPTB;NEGuPVA5PiEQvF2= NH3VVWpUSU6JRWK=
NCI-H1395 NWO2eWF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED4XW1KSzVyPUSyMlAyPjNizszN MUfTRW5ITVJ?
MHH-NB-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHkO451UUN3ME20N{4xQDF6IN88US=> MmLqV2FPT0WU
NCI-H2107 NWTWT4ptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\NWmlEPTB;NEOuOFg1PiEQvF2= MofTV2FPT0WU
NEC8 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTR2LkOzOkDPxE1? M2X1TXNCVkeHUh?=
COLO-684 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjVTWM2OD12Nj6yNlU5KM7:TR?= NELrS4FUSU6JRWK=
LS-411N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmyTWM2OD12OD60O|Q5KM7:TR?= NUDodWlUW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 3年-20℃
2年-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

文献中の引用 (62)

Frequently Asked Questions

  • Question 1
    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

    Answer: Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ